SOURCE: Biovitrum AB

October 22, 2008 02:37 ET

Biovitrum - Interim Report January 1 - September 30, 2008

STOCKHOLM, SWEDEN--(Marketwire - October 22, 2008) -

Strong financial third quarter. Product acquisition from Amgen paves the way to expanded market platform

July - September

*           Net revenues amounted to SEK 294.2 M (199.8). The profit
  for the quarter was SEK 9.8 M (-22.5),
                corresponding to earnings per share of SEK -0.21

*           Cash flow from operations was SEK -25.5 M (-46.3). Cash
  and cash equivalents and short-term
                investments as of September 30 amounted to SEK 534.1
  M (805.3).

*           Biovitrum signed an agreement with Amgen to acquire
  Kepivance® and Stemgen® and an exclusive license
                for Kineret®, paying a signing fee of USD 13 M.

*           A clinical study started of Exinalda™, for the
  treatment of fat malabsorption in patients with cystic

*           The outlook for 2008, on the whole, remains unchanged,
  excluding costs related to the product acquisition
                from Amgen and restructuring cost.

January - September

*           Net revenues amounted to SEK 826.3 M (956.9). The profit
  for the period, before restructuring and other
                onetime costs, was SEK 44.9 M (81.4). After
  restructuring and other onetime costs the result was SEK -
                88.1 M (81.4), which represents earnings per share of
  SEK -1.94 (1.78).

*           Cash flow from operations was SEK -124.0 M (-14.7).

*           The restructuring of the research organization was

*           A phase I/II study of a new long-acting factor IXFc
  protein started in the US.

*           A phase II study in patients with idiopathic
  thrombocytopenic purpura (ITP) was started.

*           Results of two clinical phase II studies were reported
  (A2A and 5HT2A projects).

*           Mimpara® has been approved by the European Commission for
  the treatment of primary
                hyperparathyroidism (PHPT). Mimpara is the first
  medication to be approved for the treatment of PHPT.

After the end of period

*           The Board of Biovitrum has decided to further focus the
  company's R&D operations by discontinuing the
                early research on small molecules. This will affect
  about 100 employees and further reduce the fixed cost
                base over time. Negotiations with the unions will be
  initiated shortly.

CEO's comments:

"The financial results for the quarter were stronger than the same period 2007 which is satisfying. The agreement with Amgen regarding acquisition of three unique biotechnological drugs is a very important milestone in our ambition to become an international specialist pharmaceutical company. We will expand Biovitrum's commercial presence to include other areas of Europe, North America, Australia and New Zealand. This partnership also paves the way for the future international launch of in-house developed drugs," says CEO Martin Nicklasson adding "our continued restructuring of the early research operations is also an important step to decrease our fixed cost base in order to focus on the development of our pipeline to the market."

For more information please contact:

Erik Kinnman, VP Investor Relations
Cell phone: +46 73 422 15 40

Martin Nicklasson, CEO
Phone: +46 8 697 2545

Göran Arvidson, CFO
Phone: +46 8 697 23 68

About Biovitrum

Biovitrum is a pharmaceutical company with operations in Sweden and in the UK. The company markets a range of specialist pharmaceuticals primarily in the Nordic countries. Using its expertise and experience Biovitrum takes scientific innovation all the way to the market and to specialist indication patients with significant medical need. Research expertise and capabilities include development and production of biotechnology therapeutics, as well as small molecule discovery and development. With revenues of approximately SEK 1.3 billion and around 500 employees, Biovitrum is a significant European specialty pharmaceutical player. Biovitrum's share is listed on the OMX Nordic Exchange in Stockholm. For more information go to


This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2008. All rights reserved.

Contact Information